Skip to content
Post Test and Evaluation
Please note that to receive credit you must achieve a score of at least 70%.
Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.
Post-Activity Test
1.
Which of the following best describes stress incontinence?
(Required.)
Overactive bladder without leakage episodes.
Leakage episodes associated with exertion (i.e., coughing, sneezing, etc.).
Leakage episodes due to strong urgency.
Leakage episodes associated with a transient condition (e.g., delirium, UTI, etc.).
2.
A factor that contributes to urge incontinence is:
(Required.)
UTI
Detrusor overactivity
Pelvic floor weakness
Urethral hypermobility
3.
A 50-year-old woman presents with a main complaint of a frequent urge to urinate (every 1–2 hours) and nocturia (1–2 times per night). She does not report incontinence episodes. The most appropriate initial diagnostic step is:
(Required.)
Urinalysis with culture
Pelvic ultrasound
Urodynamics
Cystoscopy
4.
Which of the following lifestyle changes can improve OAB symptoms?
(Required.)
Take a daily calcium supplement
Reduce weight if overweight
Cease all alcohol consumption
Daily use of feverfew
5.
You see a 52-year-old woman who complains of urinary frequency about once every hour and nocturia (1–2 times per night). She describes a strong urinary urgency and often experiences incontinence episodes. Her medical history is unremarkable, lab results are within normal limits, and urinalysis is normal.
According to AUA, an appropriate first-line management option for this patient is:
(Required.)
Behavioral therapy plus an antimuscarinic or beta3-agonist
Antimuscarinic therapy alone
Beta3-agonist therapy alone
Antimuscarinic plus beta3-agonist
All of the above
6.
When considering prescribing antimuscarinic therapy, which of the following is most accurate?
(Required.)
Some antimuscarinics have been shown to provide superior efficacy over other antimuscarinics.
Maximum effect is usually observed within 1 week of antimuscarinic use.
Dosing should start at the highest dose possible.
Extended-release formulations are preferred over immediate-release formulations.
7.
For an OAB patient who fails to get an adequate response with behavioral therapy, an appropriate second-line treatment can include any of the following except:
(Required.)
Immediate-release antimuscarinic therapy
Extended-release antimuscarinic therapy
Beta3-agonist
Botulinum toxin injection
8.
Which of the following adverse effects is most common with antimuscarinic agent use?
(Required.)
Diarrhea
Rash
Dry mouth
Postural hypotension
9.
You see a 56-year-old woman with OAB who failed to respond adequately to behavioral therapy and initiated treatment with oxybutynin 3 weeks ago. She returns for a follow-up visit and states that she stopped using her medication 1 week ago because of constipation. She did notice some improvement in OAB symptoms during the 2 weeks she was taking the medication.
Appropriate options to manage this patient include all of the following except:
(Required.)
Attempt to manage the adverse effects of her current medication
Switch to another antimuscarinic agent
Switch to a beta3-agonist
Add a beta3-agonist to the prior regimen
10.
For a patient with OAB who has failed monotherapy with different antimuscarinic agents due to inadequate response or adverse effects, an appropriate option would be all of the following except:
(Required.)
Convince the patient to live with the condition
Switch to a beta3-agonist
Consider combination therapy
Referral to a urologist
